Notably, in the case of cancer, the administration of antibodies targeting CTLA-4, followed by antibodies targeting PD-1 or a combination of both, has demonstrated effectiveness in reducing tumor growth [1,21]. This evidence concerns the gene CTLA4 and cancer.